Extended Survival and Prognostic Factors for Patients With <i>ALK</i>-Rearranged Non–Small-Cell Lung Cancer and Brain Metastasis

Abstract

Patients with brain metastases from ALK-rearranged NSCLC treated with radiotherapy (SRS and/or WBRT) and TKIs have prolonged survival, suggesting that interventions to control intracranial disease are critical. The refinement of prognosis for this molecular subtype of NSCLC identifies a population of patients likely to benefit from first-line SRS, close CNS observation, and treatment of emergent CNS disease.